Evidence map›Paper›PMID 39568433›Full record

ArticleHaematologica2025

Ultrasound-mediated catheter delivery of tissue plasminogen activator promotes thrombolysis by altering fibrin fiber thickness and clot permeability.

Robert A S Ariëns, Andrew S P Sharp, Cédric Duval

Abstract read
In one paragraph

Article in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Robert A S AriënsLeeds Thrombosis Collective, Discovery and Translational Science Department, Leeds Institute of Cardiovascular And Metabolic Medicine, University of Leeds, Leeds.
Andrew S P SharpSchool of Medicine, University College Dublin, Ireland; Department of Cardiology, Mater Misericordiae University Hospital, Dublin.
Cédric DuvalLeeds Thrombosis Collective, Discovery and Translational Science Department, Leeds Institute of Cardiovascular And Metabolic Medicine, University of Leeds, Leeds. C.Duval@leeds.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It has been proposed that low power, high frequency ultrasound can augment the ability of thrombolytic agents to dissolve clot in patients with venous thromboembolism. We created a bench model to examine what role and mechanism ultrasound may have in this process. Fibrin polymerization was analyzed through modified light-scattering experiments with the inclusion of catheter-mediated ultrasound application. We studied fibrin fiber diameters through scanning electron microscopy of ultrasound treated fibrin clots. Clot porosity was investigated using permeation tests, while fibrinolysis was analyzed through light-scattering experiments, and by changes in porosity of lysing clots under flow. Whilst application of ultrasound did not change initial fibrin polymerization, it did induce a reversible change in maximal turbidity of already formed fibrin clots. This change in turbidity was caused by a reduction in fibrin fiber diameter and was associated with an increase in clot porosity. These reversible structural changes were associated with a linear increase in fibrinolysis rates under static conditions, while an exponential increase in rates was observed under flow. The use of ultrasound augmentation of thrombolysis enhances clot dissolution through greater and more rapid fibrin degradation. This is due to conformational change created by the ultrasound in clot structure, a reversible phenomenon that may increase binding sites for lytic agent, and could potentially allow the use of lower doses and shorter infusion times of ultrasound-assisted thrombolytic to treat venous thromboembolism in vivo.

Indexed as

Blood CoagulationDrug Delivery SystemsFibrinFibrinolytic AgentsThrombolytic TherapyThrombosisTissue Plasminogen ActivatorCathetersFibrinolysisHumansPermeabilityFibrinFibrinolytic AgentsTissue Plasminogen Activator

Identifiers

PMID39568433
PMCPMC11873704

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.